Macrogenics Inc (NAS:MGNX)
$ 4.47 -0.21 (-4.49%) Market Cap: 279.97 Mil Enterprise Value: 129.75 Mil PE Ratio: 0 PB Ratio: 2.63 GF Score: 62/100

MacroGenics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript

Feb 10, 2022 / 02:00PM GMT
Release Date Price: $11.49 (-2.30%)
Charles Zhu
Guggenheim Securities, LLC - Analyst

Hello, everyone, and welcome back. I'm Charles Zhu, one of the senior biotech analysts here at Guggenheim Securities. Our next fireside chat will be with MacroGenics, a commercial-stage oncology biotech with a broad antibody-based platform. Joining us today is Scott Koenig, CEO of MacroGenics. Thank you and welcome. We always enjoy having you here at our conference, Scott. Before we hop into Q&A, could you perhaps provide a two- to three-minute overview of MacroGenics, your pipeline, and your platform?

Scott Koenig
MacroGenics, Inc. - President & CEO

It'd be my pleasure. And thanks so much for inviting us to participate in the conference today. So MacroGenics is a company that has been in over 20 years of operation. From our inception, we've been focused on immune-based therapeutics, developing proprietary platforms where we modify the structure of antibodies for various therapeutic purposes. We have three major platform technologies. One around our FC engineering, where we're able to engage immune

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot